Acella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
Acella Pharmaceuticals is recalling NP Thyroid 15 tablets because they contain less active ingredient than labeled. The recall covers bottles distributed nationwide.
What this means for you
Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.
Our severity reasoning: The FDA classified this recall as Class I, which per the rubric mandates a severity score of 5 (Critical) regardless of other factors.
Plain-English summary
Acella Pharmaceuticals, LLC is voluntarily recalling NP Thyroid 15 Thyroid Tablets, USP. The recall was initiated on April 29, 2021, because the tablets were found to be subpotent, meaning they contain less of the active ingredients levothyroxine and liothyronine than stated on the label.
The affected product is packaged in 100-count bottles (NDC 42192-327-01) and 7-count bottles (NDC 42192-327-07). The recall includes specific lots with expiration dates ranging from April 30, 2021, to March 31, 2022. A total of 66,155 bottles of the 100-count size and 26,212 bottles of the 7-count size are involved.
The product was distributed nationwide within the United States, including Puerto Rico. The FDA classified this as a Class I recall, which is the most serious type, indicating a reasonable probability that use of the product could cause serious adverse health consequences or death. Patients should stop using the recalled product and consult their healthcare provider for alternative treatment.
The recalled product
- Product
- NP THYROID 15 (LEVOTHYROXINE, LIOTHYRONINE)
- Brand
- NP THYROID 15
- Manufacturer
- Acella Pharmaceuticals, LLC
- Category
- Drug — Thyroid Hormone
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- Lots: a) M327D20-1
- M327D20-3 Exp. 03/31/2022
- M327H19-3A Exp. 07/31/2021
- M327L19-1 Exp. 04/30/2021
- b) M327D20-1 Exp. 03/31/2022
UPCs (4)
- 0342192329102
- 0342192330108
- 0342192327016
- 0342192328013
Distribution
Part of a larger recall action
This product is one of 5 recalled by Acella Pharmaceuticals, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same brand · NP THYROID 15
- CriticalAcella Pharmaceuticals Recalls Subpotent NP Thyroid 15 Prescription Tablets
FDA (Drugs) · 2021-06-02
- CriticalAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
- CriticalAcella Recalls Subpotent NP Thyroid 15 Prescription Tablets
FDA (Drugs) · 2021-06-02
- SevereAcella Recalls Subpotent NP Thyroid 15 Tablets Nationwide
FDA (Drugs) · 2021-06-02
- SevereAcella Recalls NP Thyroid 15 Tablets Due to Subpotent Levothyroxine Levels
FDA (Drugs) · 2020-10-28
Same manufacturer · Acella Pharmaceuticals, LLC
See all →- SevereNaproxen Oral Suspension Recalled for Lead and Lithium Contamination
FDA (Drugs) · 2026-05-13
- ModerateDoxycycline hyclate tablets recalled after stability testing failed dissolution specifications
FDA (Drugs) · 2025-10-15
- ModeratePrescription skin cleanser recalled nationwide due to subpotency
FDA (Drugs) · 2024-05-15
- ModerateAcella Recalls Sodium Sulfacetamide Cleansing Pads for Subpotency
FDA (Drugs) · 2022-12-07
- LowPhenytoin Sodium Injection Recalled for Missing Barcode on Vial Label
FDA (Drugs) · 2022-11-30
Same hazard · subpotent drug
See all →- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02